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ARTICLE
Inhibitor binding mode and allosteric regulation of
Na+-glucose symporters
Paola Bisignano 1,2, Chiara Ghezzi3, Hyunil Jo 1,2, Nicholas F. Polizzi1,2, Thorsten Althoff3,
Chakrapani Kalyanaraman1, Rosmarie Friemann 4, Matthew P. Jacobson 1,
Ernest M. Wright 3 & Michael Grabe1,2
Sodium-dependent glucose transporters (SGLTs) exploit sodium gradients to transport
sugars across the plasma membrane. Due to their role in renal sugar reabsorption, SGLTs are
targets for the treatment of type 2 diabetes. Current therapeutics are phlorizin derivatives
that contain a sugar moiety bound to an aromatic aglycon tail. Here, we develop structural
models of human SGLT1/2 in complex with inhibitors by combining computational and
functional studies. Inhibitors bind with the sugar moiety in the sugar pocket and the aglycon
tail in the extracellular vestibule. The binding poses corroborate mutagenesis studies and
suggest a partial closure of the outer gate upon binding. The models also reveal a putative
Na+ binding site in hSGLT1 whose disruption reduces the transport stoichiometry to the value
observed in hSGLT2 and increases inhibition by aglycon tails. Our work demonstrates that
subtype selectivity arises from Na+-regulated outer gate closure and a variable region in
extracellular loop EL5.
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Among the six human sodium-dependent glucose trans-porter (SGLT) subtypes widely expressed in the smallintestine, kidney, lung, muscle, and brain1, hSGLT1 is the
primary transporter in the intestine, while glucose reabsorption in
the kidney is accomplished mostly by hSGLT2. Patients with
mutations in the hSGLT2 gene develop a benign disorder called
familial renal glucosuria (FRG), in which sugar reabsorption in
the kidneys is impaired; however, they do not suffer any long-
term consequences2. Thus, hSGLT2 inhibition has been a primary
focus of type 2 diabetes (T2DM) research in the past decade3.
Currently approved hSGLT2 inhibitors—glucosides containing a
sugar moiety connected to an aromatic tail referred to as an
aglycon—were also shown to reduce heart failure hospitalization
rates by 35% compared to other diabetes treatments while also
cutting deaths from any cause by 32%4. While very promising,
these drugs are not free from side effects5, and the lack of
knowledge concerning the molecular determinants of action
poses a barrier to developing new chemotypes with an improved
therapeutic window. Structurally, SGLTs fall into the large
leucine-transporter (LeuT) family6, and they work by means of an
alternating access mechanism in which they first bind Na+ and
sugar from the extracellular side in a so-called outward-facing
conformation and then transition to an inward-facing con-
formation to release their cargo to the cytoplasm. The structural
basis of how inhibitors block transport is not known.
While recent studies have attempted to dock phlorizin-derived
compounds into inward-facing models of hSGLTs7, the Wright
lab has demonstrated that SGLT2 inhibitors bind from the
extracellular solution likely stabilizing a Na+-bound, outward-
facing conformation8. Thus, a detailed molecular view of this
interaction is not possible without a reliable outward-facing
model of SGLTs. While the closely related bacterial homolog
from Vibrio parahaemolyticus (vSGLT) has been solved in the
apo-9 and sugar-bound10 conformations, both structures are
inward facing, and although suitable for modeling
hSGLT–glucose complexes, our attempts to dock phlorizin into
hSGLT models built upon these templates failed. Previously,
members of the superfamily have been solved in the outward-
facing state11–13, but the sequence identities are far too low to
make reliable SGLT homology models (<8%). The outward-facing
structure of the N-acetylneuraminic acid transporter from Proteus
mirabilis (SiaT) was determined at 1.95 Å resolution14, and this
LeuT-fold transporter shares moderate sequence identity with
SGLTs (~24% identity/~46% similarity), a value that is sig-
nificantly higher than any other LeuT-fold transporter of known
structure except for vSGLT, which has similar sequence
identity to the human SGLTs as SiaT. Here we show with a
combination of computational and experimental approaches that
this outward-facing SiaT structure serves as a good template for
understanding inhibitor binding and the subtype specificity of
human SGLTs.
Results
The hSGLT1–phlorizin complex explains mutagenesis data.
Our initial attempts to dock small molecules into inward-facing
models of hSGLT built on the available vSGLT structures pro-
vided mixed results. Glucose adopts a binding pose similar to the
one observed for galactose in vSGLT. However, phlorizin fails to
adopt a reasonable pose as the glucose moiety does not occupy
the sugar binding site nor does the molecule contact any of the
protein residues known to influence inhibition (Supplementary
Methods and Supplementary Fig. 1). Therefore, we turned to SiaT
as a potential outward-facing template. We first used a combi-
nation of sequence15 and structure-based16 methods to reach a
consensus alignment between the SGLTs and SiaT
(Supplementary Methods and Supplementary Fig. 2), and we then
used the alignment to create outward-facing SGLT models based
on the SiaT structure with Modeller17. Initial glucose docking
studies were carried out on these models to confirm the role of
known residues in the glucose binding site based on published
mutagenesis data and interactions observed in the inward-facing
vSGLT co-crystal (see Methods).
Next, we docked phlorizin into the outward-facing model of
hSGLT1 using a flexible docking procedure, which allows for
motion in the small molecule around its rotatable bonds while
keeping the protein fixed. We then rescored each of the top 10
binding poses, allowing the protein side chains within 4 Å of
phlorizin to relax with the MM/GBSA18 protocol. The top-ranked
pose (green/red) occupies the same vestibule found for the MTS-
TAMRA (2-((5(6)-tetramethyl-rhodamine)carboxylamino)ethyl
methanethiosulfonate) reagent19 and shows overlap of the
phlorizin sugar moiety with the redocked glucose (transparent
yellow/red), while the aglycon tail occupies the outer vestibule
pointing towards the extracellular space (Fig. 1a, b). The sugar
moiety makes hydrogen bond interactions with residues N78,
H83, E102, Y290, W291, and K321, which have all been shown to
affect both phlorizin-dependent inhibition and sugar transport20.
Y290 has stacking interactions with both glucose and phlorizin,
but its hydroxyl group also hydrogen bonds directly to the
hydroxyl at the C1 position of phlorizin. Meanwhile, Y290’s
ability to hydrogen bond to transmembrane segment 1 (TM1) is
thought to play a role in sugar transport in vSGLT9. We tested the
importance of hydrogen bonding by mutating Y290 to F in
hSGLT1 and measuring the glucose transport and the inhibition
of steady-state, glucose-induced Na+ current as a function of
external inhibitor concentration. The inhibitory constant (Ki) for
phlorizin to the wild-type transporter was 0.22 ± 0.04 μM under
these conditions, and the value increased eightfold in the Y290F
mutant (1.8 ± 0.4 μM) consistent with the loss of a single
hydrogen bond to the aglycon tail. Glucose transport exhibited
a decrease in glucose apparent affinity (K0.5) from 0.9 ± 0.1 mM
for wild type to 35 ± 10 mM21—a nearly 35-fold change, thus
confirming the importance of the chemistry at this site for both
molecules. Glucose transport may be more impacted due to its
smaller size and the polar nature of the interactions with the
transporter, while the mostly hydrophobic nature of the
interactions between the aglycon tail and the transporter are
not impacted by the Y290F mutation. Meanwhile, F101 in TM2
exhibits π–π stacking with aromatic elements in the aglycon tail,
but no interactions with the sugar moiety (Fig. 1b) corroborating
the experimental finding that F101C increases the phlorizin Ki
170-fold while having no effect on sugar transport20. To assess
the robustness of the predicted pose, we docked the aglycon tail
alone, which is called phloretin, into hSGLT1. The smaller
phloretin molecule (yellow/red) perfectly overlaps with the
aglycon tail of phlorizin providing additional confidence in the
pose (Fig. 1c).
Structural determinants of inhibitor subtype selectivity. Next,
we wanted to explore the differences in inhibitor binding between
hSGLT1 and hSGLT2 in an attempt to understand why hSGLT2
is more easily inhibited by phlorizin-derived molecules. We
started by docking phlorizin into an outward-facing model of
hSGLT2 constructed as described for hSGLT1. The inhibitor-
binding mode is conserved between both transporters (Fig. 1d).
The sugar moiety recapitulates the same interaction landscape
observed for hSGLT1, which was expected since the glucose
binding sites are conserved. In addition, many aromatic interac-
tions with the aglycon tail are preserved (H80/H83 and F98/F101,
hSGLT2/hSGLT1 numbering, respectively); however, a notable
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sequence difference exists between both transporters in the
C-terminal end of the long extracellular loop 5 (EL5C) that
connects TM5 to TM6 (Supplementary Fig. 2). hSGLT2 has a
third aromatic residue (H268) that stacks in a parallel displace-
ment fashion with F98 to create an aromatic cage (H80, F98,
H268) around the central ring of the aglycon tail. hSGLT1 does
not form this cage because 268 is an aspartic acid, and D268
creates a salt bridge with the conserved R267 redirecting the
guanidinium group towards a cation–π interaction with the
inhibitor. The introduction of the histidine in position 268 in
hSGLT2 confers additional packing interactions absent in
hSGLT1.
Analysis of the phlorizin-docked complexes revealed only
subtle structural differences in the binding poses, which we
hesitate to attribute to the increased inhibition of hSGLT2 over
hSGLT1 without further analysis since these are homology
models and phlorizin has rather low subtype selectivity (eightfold
increase in inhibition of hSGLT2 over hSGLT1). To gain greater
insight into subtype specificity, we next docked the T2DM drug
dapagliflozin into both outward-facing models to identify
structural differences between the proteins that may explain
why this drug has a >100-fold higher potency for hSGLT222.
Dapagliflozin docks into both transporters in a very similar
manner with the sugar moiety occupying the glucose binding site
and the aglycon tail occupying the extracellular vestibule (Fig. 2).
Additionally, overlap with the phlorizin structures (transparent)
reveals that the two molecules engage with the transporters
similarly. The aromatic cage around the aglycon tail persists in
hSGLT2, and again R267 has a cation–π interaction with the tail
in hSGLT1. Again, as for phlorizin, the introduction of the
histidine in position 268 in hSGLT2 confers additional packing
interactions absent in hSGLT1. This difference might provide
some degree of selectivity, and we tested this possibility
experimentally.
To do so, we focused on two mutants: hSGLT1 D268H, which
mimics EL5C of hSGLT2, and hSGLT1 R267C, which although
conserved, only interacts with phlorizin in our hSGLT1-docked
model, but not in hSGLT2 (Fig. 2a, b). We expressed both
mutants in Xenopus laevis oocytes and recorded sugar-induced
currents (Fig. 2 and Table 1) elicited by α-methyl-D-glucopyrano-
side (αMDG)—a glucose analog, which we interchangeably refer
to as glucose throughout. Unfortunately, the R267C mutant was
not expressed in oocytes, but D268H exhibited an apparent Na+
affinity (17 ± 1.2 mM) and apparent K0.5 for glucose (1.2 ± 0.1
mM) both similar to wild type (36 ± 1 and 0.9 ± 0.1 mM,
respectively). Moreover, hSGLT1 D268H is inhibited by phlorizin
to the same degree as wild type (Ki= 0.3 ± 0.1 and 0.22 ± 0.04
μM, respectively). However, the Ki for dapagliflozin is 13-fold
lower (0.035 ± 0.011 μM) than the wild-type Ki (0.45 ± 0.02 μM),
indicating that D268H in EL5C contributes to the selectivity of
dapagliflozin but not phlorizin. The docked structures may
rationalize this difference. Phlorizin possesses a central aromatic
ring which protrudes towards EL5C making either a cation–π
interaction with R267 in hSGLT1 (Fig. 1b) or π–π and Van der
Waals packing with the imidazole of H268 in hSGLT2 (Fig. 1d).
Meanwhile, dapagliflozin lies deeper in the binding pocket, and
its central ring is too far to make a strong cation–π interaction
with R267 in hSGLT1 (Fig. 2a), but it is still able to establish
excellent interactions with H268 in hSGLT2 (Fig. 2b). Thus, the
introduction of D268H in hSGLT1 may impact dapagliflozin
binding more than phlorizin due to deeper binding of
dapagliflozin.
The outer gate partially closes over bound inhibitors. Our
analysis has focused on residues in direct contact with the inhi-
bitors, and now we turn our attention to mutations in hSGLT1
that impact glucose and phlorizin binding, but do not establish
direct contact based on the model. The first two positions are
F453 and Q457, which are on the same face of helix TM10 in the
extracellular vestibule, are both solvent exposed, and more than
10 Å away from phlorizin (Fig. 3a). Nonetheless, mutations to
cysteine at these positions increase the K0.5 of glucose 2- and 14-
fold20, respectively, while they increase the Ki of phlorizin inhi-
bition 4.5- and 27-fold20, respectively. We believe that their
influence can be understood through an induced-fit hypothesis
since the extracellular half of TM9 and TM10 and the small
intervening loop form an outer gate in the inward-facing states of
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Fig. 1 Predicted binding mode of phlorizin to hSGLT1 and hSGLT2. a Phlorizin bound to the outward-facing hSGLT1. The protein is gray, phlorizin is green
and red, and Na+ at the putative Na2/Na3 sites are yellow. EL5c (red) is represented as cartoon. The 2D structures of phlorizin and phloretin are also
shown. b Close-up view of phlorizin bound to hSGLT1. The sugar moiety occupies the sugar binding site aligning with the docked glucose (transparent
yellow/red) where it makes excellent hydrogen bonding with the protein. The aglycon tail creates face-to-face aromatic π–π interactions with H83 and F101
and a cation–π interaction with R267 on EL5C. c Phloretin and glucose bound to hSGLT1. Phloretin (yellow/red) superposes over the aglycon tail from the
phlorizin molecule (transparent green/red) in b, while glucose (yellow/red) aligns well with the sugar moiety. d Close-up view of phlorizin bound to
hSGLT2. The binding mode is conserved in hSGLT2, although the aglycon tail is more tightly packed due to an aromatic cage that forms around the central
ring made up of residues H80, F98, and H268 on EL5C
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vSGLT10, Mhp123, BetP24, and LeuT13 that closes over the sub-
strate to occlude it from the extracellular solution. If TM9-10 is
dynamic and phlorizin binding results in partial closure of the
gate, it may bring the extracellular end of TM10 into contact with
the substrates (sugar and inhibitors) as in the inward-facing
hSGLT1–glucose modeled complex and the inward-facing
occluded vSGLT structure10 (Supplementary Figs. 1a and 3).
To test our induced-fit hypothesis, we carried out 1 μs of fully
atomistic molecular dynamics (MD) simulations on the
hSGLT1–phlorizin bound complex to determine how elements
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Fig. 2 Predicted binding mode of dapagliflozin to hSGLT1 and hSGLT2. Dapagliflozin (orange/red) adopts a similar pose to phlorizin (transparent green/
red) in both hSGLT1 (a) and hSGLT2 (b). Interactions in the sugar binding site and extracellular vestibule are preserved including the electrostatic
interaction with R267 (hSGLT1) and the aromatic cage formed by H80, F98, and H268 (hSGLT2). c αMDG hSGLT1 D268H (black squares) sugar currents.
αMDG currents were measured at Vm=−50mV. The red dashed curve is a representative, wild-type hSGLT1 response. For the D268H mutant K0.5= 1.2 ±
0.1 mM, while wild-type hSGLT1 K0.5= 0.9 ± 0.1 mM. For c and d, data are normalized to the current measured at 10 mM αMDG. d Na+ dependence of
αMDG currents measured in 10 mM αMDG at Vm=−50mV. For hSGLT1 D268H K0.5= 17 ± 1.2 mM and for wild-type hSGLT1 K0.5= 36 ± 1 mM. Hill
coefficients hSGLT1 D268H and wild-type were 1.62 ± 0.03 and 1.61 ± 0.1. e Phlorizin and f dapagliflozin effect on the Qmax for hSGLT1 D268H, we
estimated a Ki= 0.3 ± 0.1 and 0.035 ± 0.011 µM for phlorizin and dapagliflozin, respectively, while the wild-type Ki= 0.22 ± 0.04 and 0.45 ± 0.02 µM. For
c–f, each data point is the mean ± SEM of n≥ 5 oocytes
Table 1 Measured Ki and K0.5 values for hSGLT2, hSGLT1 and hSGLT1 mutants
Transporter K0.5 αMDG (mM) K0.5 Na+ (mM) Ki phlorizin (μM) Ki phloretin
(μM)
Ki dapagliflozin (μM) Ki dapa-aglycon
(μM)
hSGLT1
Wild-type 0.9 ± 0.1 36 ± 1 0.22 ± 0.04 55 ± 12 0.45 ± 0.02 425 ± 50
F101C 1.1 ± 0.220 9 ± 120 37 ± 1220
D268H 1.2 ± 0.1 17 ± 1.2 0.3 ± 0.1 0.035 ± 0.011
T287C 1.4 ± 0.219 6 ± 0.219 0.2 ± 0.1
Y290C >10020 46 ± 520 36 ± 620
Y290F 35 ± 1021 20 ± 121 1.8 ± 0.4
S392A/C >10020 122 ± 1220 4 ± 120
S393A/C 4 ± 120 32 ± 320 0.5 ± 0.220
T395A 34 ± 4 104 ± 50 0.35 ± 0.10 20 ± 7 0.4 ± 0.1 187 ± 80
Q457C 13 ± 220 34 ± 220 6 ± 120
F453C 1.8 ± 0.220 21 ± 120 1 ± 0.320
hSGLT2
Wild-type 4.4 ± 0.1 22 ± 1 0.03 ± 0.01 27 ± 3 0.004 ± 0.001 110 ± 30
All parameters were estimated from SGLT current measurement in oocytes at 22 °C and each parameter is given as the mean and ±SEM of three to five estimates. The results for wild-type hSGLT1 and
hSGLT2 agree with previous reports20, 27, 65. Superscripts refer to data obtained for hSGLT1 mutants expressed in oocytes and reported previously19–21. Data reported without superscripts were
generated for this study
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of the outer gate behave. During the simulation (Supplementary
Movie 1), we observe substantial movement in the TM9-10 outer
gate (ice blue) bringing Q457 into close proximity with the
inhibitor while at the same time heading toward an occluded state
of the transporter in which both the outer gate and inner gate are
closed (Fig. 3). Partial gate closure occurs via a rigid rotation of
TM9 and a bending of TM10 around a central kink, but EL5C
(red) also plays a role in closure by forming a cap over the
aglycon tail of the inhibitor in a lid-like fashion (Fig. 3b).
Disruption of the Na3 site enhances aglycon potency. Similar to
sites in the extracellular gate, the mutation S392A impacts glucose
transport and phlorizin potency20, but it does not directly contact
the molecules. Unlike the outer gate positions, S392 fails to make
direct contact in both the inward-facing and outward-facing
models, and it is located more than 10 Å away from the substrate
in the outward-facing model (Fig. 4a). It forms part of the Na2
Na+ binding site based on the vSGLT structures9, 10, and it is
conserved throughout the solute sodium symporter family (see
Supplementary Fig. 2 for partial list). Thus, we hypothesize that
S392A disrupts Na+ binding and subsequently reduces substrate
binding through allosteric means. Experimentally, it is known
that Na+ binding precedes substrate binding from the extra-
cellular face25, 26, as ion binding opens access to the substrate and
inhibitor binding sites19 while also pre-organizing the sites for
increased binding affinity. Our recent simulations of SiaT support
the claim that ions aid in pre-organizing residues in the substrate
binding site, as we showed that the bound sialic acid was far more
stable in the binding site when Na+ was bound at Na2 and/or
Na3, despite no direct contact between the substrate and ions14. A
network of interactions exists in all LeuT transporters extending
from the Na2 site to the unwound section of TM1 that directly
contacts the transported substrate (Fig. 4a, b), and when Na+
binding at Na2 is impaired, we hypothesize that TM1 does not
adopt a conformation compatible with tight sugar and inhibitor
binding.
Motivated by the impact that Na+ binding to the Na2 site has
on substrate and inhibitor binding, coupled with the fact that
EL5C explains only part of the selectivity towards hSGLT2, we
decided to explore the primary difference between hSGLT1 and
hSGLT2—the latter binds only a single Na+, while hSGLT1 binds
2 Na+. There is little information regarding the structural
influence that binding 1 vs. 2 Na+ imparts to SGLTs; however,
our experiments suggest that hSGLT1 binds glucose five times
more tightly than hSGLT2 (Table 1), which may or may not be
related to differences in stoichiometry27. Structural insight into
ion binding comes from spectroscopic studies on LeuT13, which
has a 2-to-1 stoichiometry, and Mhp128 and vSGLT29, which
bind a single Na+ at the Na2 site like hSGLT2. Interestingly,
under saturating Na+ levels, presumably resulting in the binding
of 2 Na+ ions, LeuT adopts an outward-open conformation with
the TM9-10 gate wide open. However, saturating Na+ does not
result in an outward-open conformation for Mhp128 and
vSGLT29. Thus, we hypothesize that the second Na+ binding
event stabilizes the outer gate in an open conformation, while a
single Na+ binding at the Na2 site does not efficiently hold the
outer gate open. Since our model and simulation suggest an
induced-fit mechanism of binding, the corollary of our hypothesis
is that hSGLT2 may bind phlorizin-like molecules more tightly
because the gate closes more easily over the inhibitors to make
several contacts with residues belonging to the extracellular
portion of TM10. To test this hypothesis, we attempted to abolish
binding of Na+ to the additional Na site in hSGLT1 and measure
the influence on inhibitors and substrate.
Unfortunately, the crystallographic position of the Na1 site in
hSGLT1 is unknown. The LeuT X-ray structures revealed that a
non-conserved Na+ binding site (termed Na1) directly coordi-
nates the substrate and the protein30. Initial functional work on
hSGLT1 seemed to suggest that Na+ also binds to a Na1-like
site31 (termed Na1), but our attempts to simulate Na+ at this
position in either single or double occupancy (at Na1 and
Na2 sites, Supplementary Table 1) failed to provide a stable
configuration (Supplementary Fig. 4a, b). Next, we searched for
potential Na+ binding sites in the vicinity, and we identified a
region in hSGLT1 that provides excellent Na+ coordination from
two well-conserved polar groups (S396 and T395), an acidic
residue (D204), and coordinating backbone carbonyl from S392,
which also forms part of the Na2 site (Fig. 4a). This site is the
proposed second Na+ binding site (termed Na3) which was
resolved in the SiaT X-ray structure14. When we simulated
hSGLT1 with Na+ in Na3, in single and double (Na2 and Na3)
occupancy, the Na3 ion remained stable (Supplementary Fig. 4c,
d). As one might expect, Na3 is present in hSGLT1, but not
hSGLT2 or vSGLT (Supplementary Fig. 2). The critical difference
with hSGLT2 is the hydrophobic substitution at T395 by alanine
(Fig. 4).
To further assess the likelihood that Na3 is a suitable Na+ site,
we carried out a comprehensive analysis of all known Na+
binding sites in the RCSB database32. While such analysis has
been performed previously33, the dataset analyzed here is twice as
large. Sodium sites have a five-point coordination arising from
interactions with both side chain elements and main chain
carbonyls. The putative Na3 site in hSGLT1 (Fig. 4a and
Supplementary Fig. 5) is coordinated by Asp, Ser, and Thr side
chains, which are the first, fourth, and fifth most common
coordinating residues, as well as a Ser main chain interaction,
which is the fourth most common main chain motif (Supple-
mentary Fig. 6). Structurally similar coordination sites involving
either a Ser/Thr at positions i and i+ 1 along the primary
sequence, as observed for both hSGLT1 and SiaT, returned the
structurally unrelated sodium-calcium exchanger, which none-
theless binds Na+ with a similar coordination and also contains
an acidic group. Lastly, D204 interacts with the Na+ in a
bidentate fashion, which represents nearly half of all Asp residues
in Na+ binding sites, several of which are pictured in
Q457
EL5C
Phlorizin
TM10
t = 0 ns t = 1 μs
Starting model Partially occluded state
TM9
ba
Fig. 3 Outer gate closure explains the impact of TM9-10 residues on
substrate binding. a The outer gate residue Q457 on TM10 does not
interact with phlorizin (green/red) in the outward-facing model of hSGLT1.
b A molecular dynamics simulation of the hSGLT1–phlorizin complex
reveals significant movement in the TM9-10 outer gate bringing Q457 into
direct contact with phlorizin. Additionally, EL5C (red) closes over the top of
the inhibitor. This figure is a snapshot from the trajectory at 1 μs. Lipids and
water are not shown for clarity
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Supplementary Fig. 5d. Thus, the Na3 site in hSGLT1 has all of
the hallmarks of an excellent Na+ coordination site.
To determine if this putative position is a true sodium binding
site, we expressed the hSGLT1 T395A mutant in Xenopus oocytes
and recorded sugar-induced Na+ currents. The mutant displays
markedly decreased apparent affinity for Na+ (104 ± 50 mM)
compared to wild type (36 ± 1 mM), a loss of pre-steady-state
currents that looks more hSGLT2-like than hSGLT1-like, and a
decreased Na+-to-glucose coupling ratio from 2.2 ± 0.03 to 1.1 ±
0.08 as measured via reversal potentials (Fig. 4c), and confirmed
by estimates from Na+ Hill coefficients that were reduced from
1.7 ± 0.03 to 1.1 ± 0.3 (Supplementary Table 2). Thus, experi-
ments suggest that the Na3 site is the additional Na+ binding site,
and T395A has hSGLT2-like properties with an apparent 1-to-1
stoichiometry. Next, we measured the apparent affinity for
glucose to hSGLT1 T395A in non-saturating 100 mM external
Na+ and found a 38-fold decrease from 0.9 ± 0.1 mM in wild type
to 34 ± 4 mM (Table 1). This mutation has a dramatic effect on
glucose affinity that is comparable to Na2 binding site mutations
(S392A/C >100 mM and S393A/C ~4mM)20. Interestingly, the
mutant sugar K0.5 is eightfold lower than the value for wild-type
hSGLT2, despite position 395 being an alanine in both proteins.
Next, we measured the inhibition constant of phlorizin to
hSGLT1 T395A, and rather than increasing the inhibition
strength, as we hypothesized, it decreased inhibition ~1.5-fold
compared to the wild-type transporter (350 ± 100 vs. 220 nM,
respectively). We believe that the decrease in affinity for sugar
and the increase of Ki for phlorizin is explained by the lack of full
Na+ occupancy at the Na2 site under these conditions, which
results in failure to pre-organize the sugar binding site and
suboptimal binding of glucose and the glucose moiety. We
therefore tested the potency of the aglycon tail against this
mutant. As we predicted, phloretin potency is increased 2.7-fold
in the Na3-defective mutant (Ki= 20 ± 7 μM compared to 55 ±
12 μM for the wild type), which is marginally better than
phloretin inhibition of hSGLT2 (Ki= 27 ± 3 μM). We also tested
dapagliflozin inhibition of the hSGLT1 T395A mutant and
determined that it was unchanged from wild type, while the dapa-
aglycon, the aglycon tail of dapagliflozin, inhibited the mutant
three times better (Ki= 187 ± 80 and 425 ± 50 μM, respectively).
Finally, we attempted to introduce the Na3 site into hSGLT2 by
mutating A395 to Thr (Supplementary Table 2). Unfortunately,
this construct exhibited poor expression (about 10% of wild type),
and it was not possible to determine the stoichiometry. None-
theless, the mutant appears to have similar sugar and sodium
affinity (4 ± 0.6 and 30 ± 10 mM, respectively) to wild type (4.4 ±
0.1 and 22 ± 1 mM, respectively), while inhibition by phloretin,
dapa-aglycon, and phlorizin (Ki= 129 ± 70, >600, and 0.04 ± 0.01
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μM, respectively) are all decreased when compared to wild type
(Ki= 27 ± 3, 110 ± 30, and 0.03 ± 0.01 μM, respectively). The
reduced inhibition by phlorizin-like molecules is what we expect
if Na+ at the Na3 site stabilizes the transporter in an outward-
facing conformation. Due to large standard error, we cannot
comment on inhibition by dapagliflozin.
Discussion
In this study, our goal was to provide a structural basis for the
inhibition of SGLTs by drugs approved by the Food and Drug
Administration for the treatment of T2DM. A hallmark of these
drugs is their high potency and specificity for the hSGLT2 iso-
form uniquely expressed in the kidney, where they lower blood
glucose levels by reducing glucose reabsorption. Our approach
was to carefully construct structural models of hSGLT1 and
hSGLT2 based on the crystal structures of two bacterial homo-
logs, vSGLT and SiaT, dock the SGLT inhibitors into the
homology models, and compare the docking poses with func-
tional studies on SGLT mutant transporters. Our results reveal
that the inhibitors bind to the Na+-bound, outward-facing con-
formation of hSGLT1 and hSGLT2 with the glucose moiety of the
inhibitor in the sugar binding site and the aglycon tail in the
external vestibule. We predict that subtype selectivity arises from
two sources: (1) differences in the C-terminal end of EL5, and (2)
allosteric control of the outer gate by Na+ binding.
The validity of the hSGLT1 and hSGLT2 structural models was
demonstrated by: (1) the conservation of the hSGLT1–glucose
interaction landscape in the inward- and the outward-facing
states with respect to the sugar-bound vSGLT structure (Sup-
plementary Figs. 1a and 3), and (2) phlorizin and dapagliflozin
binding to the external surface—but not the cytoplasmic surface
—consistent with functional studies8 and data generated here
(Figs. 1 and 2 and Supplementary Fig. 1b and Table 1). The
inhibitor binding site is remarkably similar for hSGLT1 and
hSGLT2 in that the glucose moiety of the inhibitor, phlorizin and
dapagliflozin, overlaps the glucose binding site (Figs. 1 and 2).
This is not surprising since the coordinating residues are con-
served between the two transporters and mutation of these resi-
dues disrupts sugar transport and inhibition by phlorizin (Table
1). Second, the aglycon tails, phloretin and dapa-aglycon, fit into a
large vestibule leading from the external solution to the glucose
binding site (Figs. 1 and 2, and ref. 19). Aglycon/vestibule inter-
actions are dominated by π–π interactions and hydrophobic
contact with F101 and H83 in hSGLT1 and F98 and H80 in
hSGLT2. Mutation of F101 in hSGLT1 results in a 170-fold
decrease in phlorizin inhibition with no change in glucose
transport (Table 1). A significant difference between hSGLT2 and
hSGLT1 that may contribute to its greater inhibition by phlorizin
(eightfold) and dapagliflozin (>100-fold) is the presence of H268
in EL5c, which gives rise to an aromatic cage around the central
ring of the aglycon composed of three residues rather than two
(Fig. 1b, d). D268 is the equivalent residue in hSGLT1, and it
forms a salt bridge with the adjacent conserved residue R267.
Simply mutating D268 to histidine in hSGLT1, so that it
resembles EL5C in hSGLT2, leads to a 13-fold increase in dapa-
gliflozin potency arising from improved packing interactions
based on our docked models (Table 1). However, this single point
mutation in EL5C cannot explain the >100-fold selectivity of
dapagliflozin for hSGLT2 over hSGLT1.
One discrepancy between the structural models and functional
data concerns the mutation of two residues on the solvent-
exposed face of helix TM10, Q457, and F453 in hSGLT1, that
decrease glucose transport and phlorizin-dependent inhibition
despite no interactions in the models (Table 1). Our fully ato-
mistic molecular dynamic simulations reveal substantial rotation
of TM9 and bending in the external half of TM10 upon phlorizin
binding bringing Q457 close to the inhibitor, while EL5C forms a
cap over the inhibitor (see Figs. 3 and 5 and Supplementary
Movie 1). Thus, our simulations together with mutagenesis stu-
dies suggest that the inhibited state of the transporters involves
rearrangements in the extracellular gate.
Another major difference between hSGLT2 and hSGLT1 is that
glucose transport is driven by one Na+ ion, not two, and so we
turned to Na+ stoichiometry as another potential determinant of
inhibitor specificity. We identified a putative Na+ binding site in
hSGLT1 (Na3), not present in hSGLT2 (Fig. 4), which is below
the conserved Na2 site (see Supplementary Fig. 5 and ref. 14). The
Na3 site is also present in SiaT14, but is distinct from the LeuT
Na1 and BetP Na1’ sites, and while having the same name, it is
not the same site identified as Na3 in GlyT2 (see Supplementary
Fig. 7 for an overview of LeuT-fold Na+ binding sites). Mutation
of a Na3 coordinating residue, T365A, in hSGLT1 dramatically
reduces Na+ affinity, and impacts glucose transport and inhibitor
potency. Most importantly, the T365A mutant is more easily
inhibited by the aglycon tail of phlorizin and dapagliflozin
(Table 1), supporting our hypothesis that inhibitors bind via an
induced-fit mechanism as shown in the cartoon in Fig. 5. In this
model, sites in EL5C (red) provide some of the energetics of
inhibitor binding, while also providing some of the subtype
selectivity. A synergistic factor comes from partial closure of the
outer gate, which is more energetically favorable with only a
single Na+ at the Na2 site (hSGLT2) than it is with 2 Na+ ions
bound (hSGLT1).
There are several lines of evidence supporting the hypothesis
that Na+ allosterically controls the outer gate. Extensive
Na3
Na2
EL5C
Na2
Phlorizin-like molecules
hSGLT2
hSGLT1
Outward open Partially occludedOutward occludedOutward open
Induced fit
with outer gatea
b
c
d
Fig. 5 Allosteric model of inhibitor binding to SGLTs. The binding of phlorizin-like inhibitors to the outward-facing state of SGLTs leads to a partial closure
of the TM9-10 outer gate in an induced fit mechanism. a, c Binding of 2 Na+ to hSGLT1 stabilizes the outer gate in an open conformation making it less
favorable for the gate to close over the aglycon tails of inhibitors. b, d The absence of the Na3 site in hSGLT2 makes partial closure and inhibitor binding
more favorable and therefore the inhibitors more potent. Additionally, elements of EL5C (red) contribute to better binding to hSGLT2
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biochemical data show that external Na+ is required for the
alkylation of cysteine residues in the glucose binding site in
hSGLT120, and active site voltage clamp demonstrates that
external Na+ controls the opening and closing of the external gate
in real time (1–10 ms)19. In addition, mutation of Na2 site resi-
dues blocks the voltage-dependent opening and closing of the
outer gates31. As already discussed, vSGLT29 and Mhp128, both of
which have 1-to-1 stoichiometries, fail to fully open their outer
gates in high Na+, while cysteine accessibility studies of LeuT and
SERT, which have 2-to-1 stoichiometries, both require Na+
binding to open the outer gate34. Similarly, double
electron–electron resonance studies on LeuT reveal that high Na+
levels cause the outer gate to open35. Thus, we wondered whether
we could engineer in a second Na+ site to hSGLT2 by mutating
the residue A395 to T (the Na3 binding residue present in
hSGLT1). Although hampered by very low expression levels in
oocytes, the results partially corroborate the gating hypothesis in
that aglycon tails and phlorizin showed lower levels of inhibition
to the mutant hSGLT2 than the wild type (Supplementary
Table 2).
In summary, we propose a structural model that explains inhi-
bitor binding to the Na+-bound, outward-facing conformation of
hSGLTs that largely accounts for their functional activity. While we
have identified two independent components of subtype selectivity,
it still remains to be shown that these elements, together with
saturated Na2 occupancy, fully account for the higher potency of
the drugs to the renal hSGLT2 isoform. The first component is the
formation of a hydrophobic cage surrounding the central ring of
the aglycon in hSGLT2, but only partially in hSGLT1. The addi-
tional aromatic residue in hSGLT2 is H268 on an extracellular loop
that forms a cap over the bound inhibitor. The second component
is differences in sodium binding, where the lower potency of
inhibitor binding to hSGLT1 is due to the second sodium stabi-
lizing the transporter in an open conformation that lacks stabi-
lizing interactions between the inhibitor and elements of the
transporter found on the mobile extracellular gate. Further vali-
dation of our predictions awaits the crystal structures of human
SGLTs, molecular simulations, and functional assay on mutants;
together, these studies will lead to improved drugs.
Methods
Sequence alignment and homology modeling. Both a primary sequence align-
ment (EMBOSS stretcher15) and a structural alignment (MatchMaker16 within
Chimera v1.10.136) were determined for vSGLT (PDB ID 3DH4) and SiaT (PDB
ID 5NV9 throughout) followed by hand adjustments to arrive at a consensus
alignment used for model building. hSGLT1 and hSGLT2 were added to the
alignment based on previously published alignments to vSGLT10. Outward-facing
models were then created with this alignment using Modeller v9.1517 and the
transmembrane stretches of TM1-10 from SiaT and the extracellular loops from
vSGLT (PDB ID 3DH4) as templates. Outward-facing vSGLT models also included
TM0 and a C-terminal tag from the apo vSGLT structure (PDB ID 2XQ2). In all
cases, one hundred models were generated using the variable target function
method37, and the best model was selected based on DOPE38 score and visual
inspection.
MD simulations. Models were oriented in the membrane using the OPM server39
or superposition to previously oriented models followed by embedding with
CHARMM-GUI40 in a 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine mem-
brane. Final systems 112,000 atoms in size were neutralized in 150 mM NaCl. The
CHARMM3641 parameter set with the TIP3P water model42 was used with
GROMACS v2016.143 for the MD engine. Equilibration consisted of 10,000 steps of
minimization, or until maximum forces dropped below 5000 kJ/mol/nm, followed
by 75 ps of NVT (constant-temperature, constant-volume) dynamics and then 0.3
ns of NPT (constant-temperature, constant-pressure) dynamics. During equili-
bration, restraints on the bound ions, backbone, side chain, lipid heavy atoms, and
dihedral angles of the lipid tails were reduced from 2–10 kcal/mol/Å2 to zero.
Production runs ranged from 7 to 30 ns. Temperature (303.15 K) was maintained
using the Berendsen44 algorithm during equilibration followed by Nosé–Hoover45
for production using a 1 ps coupling time constant. Pressure (1 bar) was main-
tained with a Berendsen44 barostat followed by a Parrinello–Rahman46 barostat
with a 5 ps period. The time step was 1 fs during equilibration and 2 fs during
production. Hydrogen atoms were constrained with LINCS47, long-range electro-
statics were computed with particle mesh Ewald, and van der Waals and Cou-
lombic interactions were switched between 10 and 12 Å.
The best hSGLT1–phlorizin model from the docking run was simulated with
Na+ bound to the Na2 and Na3 sites. The system was again prepared with the
CHARMM-GUI webserver in an identical manner to the Na+ simulations and
converted with in-house scripts into the AMBER format. Simulations were carried
out using the ff14SB AMBER48 parameter set for the protein, the
Joung–Cheatham49 parameters for the monovalent ions, LIPID1750 for the lipids,
and the gaff51 force field for phlorizin. The TIP3P model was used to simulate the
water. Phlorizin geometry was first optimized and its electrostatic potential was
calculated with Gaussian v9-E0152 with the 6–31 G* basis set. Next, the RESP53
charges were fitted into the electrostatic potential with antechamber54 and the force
field parameters, topology, and starting coordinates were generated with
AmberTools. Simulations were carried out with the pmemd55 MD engine on
GPUs. Minimization consisted of 10,000 steps, switching from the steepest descent
algorithm to conjugated gradient after 5000 steps. The system was then gradually
heated from 0 to 303.15 K over 15 ps, and harmonic restraints with a spring
constant of 10 kcal/mol/Å2 were applied to all heavy atoms except water oxygens.
After reaching 100 K, we switched from NVT to NPT. After 105 ps, force constants
of 10, 5, and 2.5 kcal/mol/Å2 were applied to the substrates and nearby residues
(within 5 Å), protein, and lipid headgroups, respectively. Restraints were gently
removed over the next ~8 ns, and the system was simulated for 1 μs. Pressure (1
bar) was maintained using a semi-isotropic pressure tensor and the Berendsen
barostat. Temperature was maintained with the Langevin thermostat with a friction
coefficient of 1 ps−1. The SHAKE56 algorithm was used with a 2-fs time step. A
non-bonded cutoff of 10 Å was used and electrostatics were calculated using the
particle mesh Ewald method.
Virtual screening. The Small Molecule Drug Discovery Suite 2016-1 (Schrödinger
LLC)57 was used for all the docking calculations. Protein isoforms were prepared in
a ready-to-dock-format with the Protein Preparation Wizard. The hydroxyl group
orientations and protonation states were assigned at pH 7 using PROPKA58 in Epik
v3.5. Small molecules were drawn with Maestro v10.5, and their protonation states
and tautomers assigned at pH 7.0 ± 2 in Epik v3.5. Conformers were assigned using
LigPrep v3.7 with the OPLS force field v359. Docking was performed as follows.
Side chain rotamers in the sugar binding site in both hSGLT1 and hSGLT2 were
optimized with induced-fit docking60. The models were first aligned to the
galactose-bound vSGLT structure (PDB ID 3DH4), and restraints were applied to
the heavy atoms of the redocked sugar allowing 1.5 Å deviation from the binding
mode observed in the X-ray structure. The Standard Precision61 scoring function
was used for the first docking stage followed by the more accurate XP62 function
for refinement. Next, small molecules (phlorizin, phloretin, dapagliflozin, dapa-
aglycon) were docked into both hSGLT1 and hSGLT2 allowing for small molecule
flexibility while keeping the protein rigid to obtain a maximum of 10 optimal
binding poses. Prior to docking, a 6 × 6 × 8Å3 docking grid was erected on the
glucose-optimized binding sites. The Glide XP scoring function was employed, and
the strain energy was included in the final docking score. Planarity of aromatic
groups was enforced and only trans conformations of amide groups were allowed.
These 10 poses for each molecule were then rescored with the MM/GBSA protocol
to allow side chain relaxation around the small molecule, using the VSGB solvent
model63 and an implicit membrane. Membrane boundaries were determined based
on results from MD simulations, and protein atoms up to 4 Å from the molecule
were allowed to move. Final binding poses were picked based on a combination of
visual inspection, chemical intuition, and score.
Chemistry. Dapa-aglycon22 was synthesized by copper-catalyzed hydroxylation of
the corresponding aryl iodide64. A mixture of 1-chloro-2-(4-ethoxybenzyl)-4-
iodobenzene (1 mmol), CuI (0.3 mmol), 1,10-phenanthroline (0.6 mmol), and
CsOH (3.3 mmol) in dimethyl sulfoxide/water (3:1, 4 ml) was stirred at room
temperature for 1 h and then heated to 100 °C for 2 h. After cooling, liquid was
transferred to a separatory funnel and diluted with ethyl acetate and washed with 1
M HCl. The organic layer was dried over Na2SO4 and concentrated under reduced
pressure. The crude product was purified by flash column chromatography using
hexanes-ethyl acetate as eluents. Proton nuclear magnetic resonance (1H NMR)
(300MHz, CDCl3) δ 7.21 (1H, d, J= 8.5 Hz), 7.09 (2H, d, J= 8.4 Hz), 6.83 (2H, d,
J= 8.4 Hz), 6.62 (1H, dd, J= 8.5, 2.7 Hz), 6.55 (1H, d, J= 2.6 Hz), 4.76 (1H, s), 4.01
(2H, dd, J= 13.9, 6.9 Hz), 3.96 (2H, s), 1.40 (3H, dd, J= 6.9, 6.9 Hz). The activity of
this dapa-aglycon was consistent with that observed previously22.
Molecular biology. Mutants of hSGLT1 in pBluescript65 and hSGLT2 in
pT7TS66, 67 were prepared using the QuickChange site-directed mutagenesis kit
(Statagene La Jolla, CA, USA), using the primers provided in Supplementary
Table 3. Capped wild-type and mutant cRNA was synthesized from linearized
plasmids using T3 and T7 mMessage mMachine kits (Ambion).
Functional expression of hSGLT1 in oocytes. Xenopus laevis (Nasco) oocytes
(V–VI) were prepared as previously described20 and injected with 50 nl of cRNA
(1 μg/μl). In the case of hSGLT2, co-injection of MAP17 cRNA was required for
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transport activity67, 68. hSGLT1 and hSGLT2 activity was confirmed by the mea-
surement of sodium-dependent uptake of 50 μM α-methyl-D-glucopyranoside as
described previously20. Briefly, oocytes were incubated for 30 min in the presence
of 50 μM αMDG (5 μM [14C]αMDG) in a buffer containing (in mM) 100 NaCl, 2
KCl, 1 MgCl2, 1 CaCl2, and 10 N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic
acid) (HEPES)/Tris (pH 7.5). After incubation, oocytes were rinsed thoroughly
with ice-cold buffer containing (mM) 100 choline Cl–, 2 KCl, 1 MgCl2, 1 CaCl2,
and 10 HEPES/Tris (pH 7.5), individually lysed with 5% sodium dodecyl sulfate,
and assayed for radioactivity.
Electrophysiology. Injected oocytes were incubated at 18 °C, and after 3–4 days,
two electrode voltage clamp experiments were performed as previously described20.
Briefly, SGLT inward glucose currents were measured as a function of the external
Na+ (0–100 mM NaCl), sugar (0–100 mM αMDG), and inhibitors (0.001–100 μM).
Steady-state and hSGLT1 capacitive currents were recorded using voltage steps
from a holding voltage, Vh of −60 mV, to voltages in the range of −180 to +50 mV
in 20 mV increments. The apparent affinity of αMDG, K0.5, was estimated from
plots of the inward current as a function of the external αMDG concentration.
Under our experimental conditions, K0.5 is a close approximation of the αMDG
binding constant to the Na+-bound outward conformation of SGLT. The apparent
affinity for Na+, K0.5, was estimated from plots of the αMDG inward current as a
function of external Na+ concentration. For hSGLT1 the interpretation of K0.5 is
more complex owing to the presence of two Na+ binding sites. In this case, the K0.5
is a lumped coefficient for Na+ binding to the two sites in the outward-facing
hSGLT1 conformation. The inhibitor constants for phlorizin and derivatives were
determined by: (i) measuring the effect of increasing concentrations of inhibitor on
the αMDG inward currents measured in presence of NaCl (100 mM) and a αMDG
equivalent to K0.5 of the specific mutant or wild type22, and (ii) from the inhibitor
effect on hSGLT1 capacitive currents in the absence of sugar20. The Na+-to-αMDG
stoichiometry was determined from the reversal potential measurements using the
Gibbs free energy as previously described67. The stoichiometry determinations
were reinforced by estimates of αMDG and Na+ Hill coefficients, and in some
cases, by measurement of 22Na and [14C]αMDG uptakes under voltage clamp20, 21.
Na+ binding site analysis. We compiled a non-redundant protein structural
database via the Advanced Search dialog at rcsb.org with the following search
criteria (3 June 2018): {Chemical ID(s): NA and; Polymeric type is Free and;
Experimental Method is X-RAY and; Resolution is between 0.0 and 2.5 and;
Sequence Length is between 40 and 100000 and; Chain Type: there is a Protein
chain but not any DNA or RNA and; XrayRefinementQuery: refine.ls_R_fac-
tor_obs.comparator= between refine.ls_R_factor_obs.min= 0 refine.ls_R_fac-
tor_obs.max= .3 and; Representative Structures at 50% Sequence Identity}. The
resulting database was comprised of 1750 proteins containing sodium ions, filtered
at 50% sequence similarity and with X-ray resolution ≤2.5 Å and Robs ≤0.3. The
PDB files were downloaded from the RCSB website, and biological assemblies were
created via the python program Prody69. Labels of unique chains (by sequence
similarity) were saved via a custom table of the RCSB search results. The protein
structures were protonated by the program Reduce70 with N/Q/H residues allowed
to flip.
Data availability
Data supporting the findings of this manuscript are available from the corre-
sponding authors upon reasonable request. A reporting summary for this Article is
available as a Supplementary Information file.
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